Telithromycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Category | Antibiotics |
Catalog number | BBF-03847 |
CAS | 191114-48-4 |
Molecular Weight | 812.00 |
Molecular Formula | C43H65N5O10 |
Purity | >98% |
Online Inquiry
Description
Telithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the carbon at position 6 has been methylated, as is the case in clarithromycin, to achieve better acid-stability. It is used to treat community acquired pneumonia of mild to moderate severity.
Specification
Related CAS | 173838-31-8 (Deleted CAS) |
Synonyms | HMR-3647; HMR 3647; HMR3647; RU-66647; RU 66647; RU66647; Ketek |
Storage | Store at -20°C |
IUPAC Name | (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-15-[4-(4-pyridin-3-ylimidazol-1-yl)butyl]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone |
Canonical SMILES | CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C |
InChI | InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37+,38-,40+,42-,43-/m1/s1 |
InChI Key | LJVAJPDWBABPEJ-XZVSULPPSA-N |
Source | Semi-synthetic |
Properties
Appearance | White to Light Yellow Powder |
Application | Antibacterial |
Antibiotic Activity Spectrum | Gram-positive bacteria |
Boiling Point | 966.2°C at 760 mmHg |
Melting Point | 176-188°C |
Density | 1.26 g/cm3 |
Solubility | Soluble in DMF, DMSO, Ethanol, Methanol, Water |
LogP | 3 |
Toxicity
Carcinogenicity | No indication of carcinogenicity to humans (not listed by IARC). |
Mechanism Of Toxicity | Telithromycin acts by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci (e.g., Streptococcus pneumoniae) in the presence of resistance mediated by methylases (erm genes) that alter the domain V binding site of telithromycin. Telithromycin may also inhibit the assembly of nascent ribosomal units. Compared to erythromycin A, telithromycin binds to the 23S rRNA with 10 times greater affinity in erythromycin-susceptible organisms and 25 times greater affinity in macrolide-resistant strains. This increased binding affinity may be conferred by the C11-12 carbamate side chain of telithromycin. The side chain appears to maintain binding at domain II in the presence of resistance mediated by alterations in domain V. |
Toxicity | LD50 > 2000 mg/kg (PO in rats). |
Reference Reading
Spectrum
Predicted GC-MS Spectrum - GC-MS (TMS_1_1) - 70eV, Positive
Experimental Conditions
Ionization Energy: 70 eV
Chromatography Type: Gas Chromatography Column (GC)
Instrument Type: Single quadrupole, spectrum predicted by CFM-ID(EI)
Mass Resolution: 0.0001 Da
Molecular Formula: C43H65N5O10
Molecular Weight (Monoisotopic Mass): 811.4731 Da
Molecular Weight (Avergae Mass): 812.0037 Da
Derivative Type: TMS_1_1
Predicted LC-MS/MS Spectrum - 10V, Positive
Experimental Conditions
Collision Energy: 10 eV
Instrument Type: QTOF (generic), spectrum predicted by CFM-ID
Mass Resolution: 0.0001 Da
Molecular Formula: C43H65N5O10
Molecular Weight (Monoisotopic Mass): 811.4731 Da
Molecular Weight (Avergae Mass): 812.0037 Da
Recommended Products
BBF-04736 | 3-Indolepropionic acid | Inquiry |
BBF-03709 | Nemadectin | Inquiry |
BBF-05827 | Spliceostatin A | Inquiry |
BBF-04301 | Tulathromycin A | Inquiry |
BBF-01210 | Emericid | Inquiry |
BBF-02577 | Pneumocandin C0 | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2